AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q4 FY24 results · Jan–Mar 2024
AstraZeneca Pharma India reported revenue from operations of ₹383.20 crore (up 34.6% from Q4 FY23) and net profit of ₹39.48 crore (up 128.6% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a standalone basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 383.20 | 284.70 | +34.6% | 305.79 | +25.3% |
| Other income | 8.66 | 8.00 | +8.3% | 9.66 | −10.3% |
| Total income | 391.86 | 292.70 | +33.9% | 315.45 | +24.2% |
| Profit before tax | 54.35 | 23.28 | +133.5% | 20.40 | +166.4% |
| Net profit for the period | 39.48 | 17.27 | +128.6% | 15.80 | +149.8% |
| EPS, basic (₹) | 15.79 | 6.91 | +128.6% | 6.32 | +149.9% |
| Net margin (%) | 10.3 | 6.1 | 5.2 |
Standalone
- Filed with BSE
- 28 May 2024, 15:13 IST
- Board meeting
- 27 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE